An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3
subpopulations of participants with previously treated progressive metastatic ( spread of a
cancer from one organ or part to another non-adjacent organ or part) breast cancer (abnormal
tissue that grows and spreads in the body until it kills) participants.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.